APRE - Aprea Therapeutics shares rise after leukemia treatment gets FDA orphan drug status

Aprea Therapeutics shares jump ([[APRE]] +15.3%) announces that the U.S. FDA has granted Orphan Drug designation to eprenetapopt for treatment of acute myeloid leukemia ((AML)).Orphan Drug status is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases or conditions affecting fewer than 200K people in the U.S.The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. upon approval.

For further details see:

Aprea Therapeutics shares rise after leukemia treatment gets FDA orphan drug status